Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
2006-01-10
2006-01-10
Badio, Barbara P. (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
C514S182000, C540S107000, C540S108000, C552S549000, C552S551000
Reexamination Certificate
active
06984634
ABSTRACT:
This invention is directed to compounds that provide for sustained systemic concentrations of therapeutic or prophylactic agents following administration to animals. This invention is also directed to pharmaceutical compositions including and methods using such compounds.
REFERENCES:
patent: 3326758 (1967-06-01), Irmscher et al.
patent: 4560512 (1985-12-01), Firestone
patent: 5352682 (1994-10-01), Sipos
patent: 5462933 (1995-10-01), Kramer et al.
patent: 5541348 (1996-07-01), Ayra et al.
patent: 5646272 (1997-07-01), Kramer et al.
patent: 5668126 (1997-09-01), Kramer et al.
patent: 5695738 (1997-12-01), Anderson et al.
patent: 5725840 (1998-03-01), Klaveness et al.
patent: 5942248 (1999-08-01), Barnwell
patent: 6143738 (2000-11-01), Zasloff
patent: 6288041 (2001-09-01), Chaki et al.
patent: 0272462 (1988-06-01), None
patent: 11-60594 (1999-03-01), None
patent: 11-60954 (1999-03-01), None
patent: WO 01/76531 (2001-10-01), None
patent: WO 02/100347 (2002-12-01), None
Database esp@cenet on STN, PN KR9701149 (Kim Young-Man et al.), Jan. 29, 1997, Abstract only.
Swaan et al., Preface. Advanced Drug Delivery Reviews. 1996, vol. 20, pp. 1-3, see entire document.
Russell-Jones et al., “Vitamin B12 Mediated Oral Delivery Systems for Granulocyte-Colony Stimulating Factor and Erythropoietin,”Bioconjugate Chemistry, 1995, vol. 6, pp. 459-465, see entire document.
Shah et al., “Transcellular Delivery of an Insulin-Transferrin Conjugate in Enterocyte-like Caco-2 Cells,”J. of Pharm. Sci., Dec. 1996, vol. 85, No. 12, pp. 1306-1311, see entire document.
Swaan et al., “Use of intestinal and hepatic bile acid transporters for drug delivery,”Advanced Drug Delivery Reviews, 1996, vol. 20, pp. 59-82, see especially pp. 75 and 76.
Kagedahl et al., “Use of the Intestinal Bile Acid Transporter for the Uptake of Cholic Acid Conjugates with HIV-1 Protease Inhibitory Activity,”Pharm. Res., 1997, vol. 14, No. 2, pp. 176-180, see entire document.
International Search Report mailed Jan. 22, 2002 from PCT/US01/42513.
International Search Report mailed Jan. 23, 2002 from PCT/US01/31486.
International Search Report mailed Dec. 31, 2001 from PCT/US01/31394.
Adibi, S.A., “The oligopeptide transporter (Pept-1) in human intestine: Biology and Function”,Gastroenterology, vol. 113, pp. 332-340, 1997.
Baringhaus, K.H., et al., “Substrate specificity of the ileal and hepatic Na+/ bile acid cotransporters of the rabbit. II. A reliable 3D QSAR pharmacophore model for the ileal Na+/ bile acid cotransporter”,J. Lipid Res., vol. 40, pp. 2158-2168, 1999.
Bryans, J. S., et al., “3-Substituted GABA analogs with central nervous system activity: a review”,Med. Res. Rev., vol. 19, pp. 149-177, 1999.
Bundgaard, H., inDesign of Prodrugs(Bundgaard, H. Ed.), Elsevier Science B.V., pp. 1-92, 1985.
Dieck, S.T., et al., “The peptide transporter PepT2 is expressed in rat brain and mediates the accumulation of the fluorescent dipeptide derivative β-Ala-Lys-NE-AMCA in astrocytes”,GLIA, vol., 25, pp. 10-20, 1999.
Ho, N. F. H., “Utilizing bile acid carrier mechanisms to enhance liver and small intestine absorption”,Ann. N. Y. Acad. Sci., vol. 507, pp. 315-329, 1987.
Jezyk, N., et al., “Transport of Pregabalin in Rat Intestine and Caco-2 Monolayers”,Pharm. Res., vol. 16, pp. 519-526, 1999.
Kagedahl, M., et al., “Use of the intestinal bile acid transporter for the uptake of cholic acid conjugates with HIV-1 protease inhibitory activity”,Pharm. Res., vol. 14, pp. 176-180, 1997.
Kim, D.C., “Evaluation of bile acid transporter in enhancing intestinal permeability of renin-inhibitory peptides”,J. Drug Targeting, vol. 1, pp. 347-359, 1993.
Kramer, W, et al., “Liver-specific drug targeting by coupling to bile acids”,J. Biol. Chem., vol. 267, pp. 18598-18604, 1992.
Kramer, W., et al., “Intestinal absorption of peptides by coupling to bile acids”,J. Biol. Chem., vol. 269, pp. 10621-10627, 1994.
Kramer, W., “Bile acid derived HMG-CoA reductase inhibitors”,Biochim. Biophys. Acta., vol. 1227, pp. 137-154, 1994.
Kramer, W., et al., “Substrate specificity of the ileal and hepatic Na+/ bile acid cotransporters of the rabbit. I. Transport studies with membrane vesicles and cell lines expressing the cloned transporters”,J. Lipid Res., vol. 40, pp. 1604-1617, 1999.
Kullak-Ublick, G.A., et al., “Hepatobiliary transport”,J. Hepatology, vol. 32 (Suppl. 1), pp. 3-18, 2000.
Leibach, et al., “Peptide transporters in the intestine and the kidney”,Ann. Rev. Nutr., vol. 16, pp. 99-119, 1996.
Mills, C.O., et al., “Ileal absorption of tyrosine-conjugated bile acids in Wistar rats”,Biochim. Biophys. Acta, vol. 926, pp. 154-159, 1987.
Navia, M.A, “Design principles for orally bioavailable drugs”,Drug Discovery Today, vol. 1, pp. 179-189, 1996.
Petzinger, E., et al., “Hepatobiliary transport of hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors conjugated with bile acids”,Hepatology, vol. 22, pp. 1801-1811, 1995.
Swaan, P.W.,Use of the intestinal and hepatic bile acid transporters for drug delivery, Adv. Drug Delivery Rev, 1996, 20, pp. 59-82.
Swaan, P.W., et al., “Enhanced transepithelial transport of peptides by conjugation to cholic acid”,Bioconj. Chem, vol. 8, pp. 520-525, 1997.
Tsuji, A., et al., “Carrier-mediated intestinal transport of drugs”,Pharm. Res., vol. 13, pp. 963-977, 1996.
Wong, et al., “Electrophysiological characteristics of the proton-coupled peptide transporter PEPT2 cloned from rat brain”,Am. J. Physiol., vol. 275, pp. C967-C975, 1998.
Wess, G., et al., “Synthesis of Bile Acid -Drug Conjugates: Potential Drug-Shuttles for Liver Specific Targeting”,Tetrahedron Letters34(5):819-822 (1993).
Wess, G., et al., Preparation of 3α-and 3β-ω-Aminoalkoxy)-7 α, 12α-Dihydroxy-5β-Cholanioic Acid Esters: Versatile Shuttles for Drug Targeting,Tetrahedron Letters34(5):817 (1993).
European Search Report from EP01 97 8853 dated May 25, 2005.
Cundy Kenneth C.
Gallop Mark A.
Badio Barbara P.
XenoPort, Inc.
LandOfFree
Bile-acid conjugates for providing sustained systemic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Bile-acid conjugates for providing sustained systemic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bile-acid conjugates for providing sustained systemic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3564073